Sensorium Therapeutics key facts
as of Oct 2026- Developer of a therapeutic discovery platform designed to identify compounds for treating brain and mental health conditions.
- Sensorium Therapeutics is valued at approximately $47.0M as of Oct 2026 (last reported valuation).
- It has raised $69.7M across 3 recorded rounds; the latest was Early Stage VC ($26.8M) in Jan 2025.
- Notable investors include Service Provider Capital, Dolby Family Ventures, Hatteras Venture Partners, Mission BioCapital, Ocama Partners — 16 tracked in total.
- Sensorium Therapeutics has filed 5 Form Ds with the SEC since 2021, most recently Jul 2025 ($26.8M sold to 19 investors).
- Status: Privately Held (backing).
Sensorium Therapeutics's last reported valuation, Sep 2022. Nothing priced has surfaced since.
- ·The complete investor list: 16 names
- ·Watch Sensorium Therapeutics: the Monday email on marks, rounds and moves
Sensorium Therapeutics funding rounds
3 roundsWho backs Sensorium Therapeutics
16+Sensorium Therapeutics valuation
Sensorium Therapeutics's last reported valuation was $47 million in Sep 2022. No priced round, secondary trade or fund mark has surfaced since.
How much has Sensorium Therapeutics raised?
Sensorium Therapeutics has raised $69.7 million across 3 recorded rounds since 2021. The largest was a $9 million early-stage round in Jul 2021; the most recent was a $26.8 million early-stage round in Jan 2025.
Sensorium Therapeutics has filed 5 Form Ds with the SEC since 2021, most recently in Jul 2025 ($26.8 million sold to 19 investors).
Sensorium Therapeutics investors
16 investors are on record for Sensorium Therapeutics, including Service Provider Capital, Dolby Family Ventures, Hatteras Venture Partners and Mission BioCapital. By type, the record holds 4 venture capital firms and 1 family office. The early-stage round in Jan 2025 drew 19 investors.
About Sensorium Therapeutics
Developer of a therapeutic discovery platform designed to identify compounds for treating brain and mental health conditions. The company's platform utilizes a computational approach that integrates artificial intelligence, chemistry, and neuroscience to accelerate the identification of new drug candidates, enabling researchers and clinicians to develop novel treatments and provide patients with access to effective therapeutic options that address significant unmet medical needs.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2021
- Employees
- 26
- Website
- sensorium.bio/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.